Feed ALVO
AL

Alvotech

ALVO · NASDAQ

$5.02 -0.59% (-$0.03)
1M +29.38%
Market Cap $1.70B
P/E Ratio -
Div. Yield -
ROE -

Bulios Fair Price

$7.47

48.8% upside

Trenutna cena

$5.02

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica ALVO trenutno podcenjena glede na svojo tržno ceno. Kako deluje?

Odkleni pošteno ceno

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Weak
0/9
Valuation
51 /100
Fair
P/S 3.45x
P/E N/A
P/FFO N/A
Growth
100 /100
Growing
Rev. growth 91.85%
EPS growth N/A
Book val. growth N/A
Profitability
32 /100
Weak
Gross margin 60.45%
FCF margin 61.03%
Net margin 36.51%
Quality
63 /100
Average
ROIC 20.17%
Asset turnover 0.31x
ROA 11.31%
Debt
35 /100
Moderate
Current ratio 1.65x
Int. coverage -0.22x
Debt/Equity N/A
Stability
13 /100
Unstable
Beta 0.18x
Profitable years 1
Rev. volatility 242.90%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o ALVO
Online

O podjetju

Alvotech (ALVO) is a fully integrated specialty biopharmaceutical company focused exclusively on the development and manufacture of high-quality biosimilar medicines. The company's goal is to improve patients' health and quality of life around the world by increasing access to effective therapies for various ailments.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Lisa Graver

Employees

1,279

Headquarters

Luxembourg

Prihajajoči dogodki

11 NOV.

Earnings

Upcoming earnings report

56d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.